The distribution of tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML) is influenced by the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). This evidence concerns the gene ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive.